Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-γ retroviral vector in melanoma patients

Cancer Gene Therapy

Volumn 7, Issue 9, 2000, Pages 1220-1230

  Fujii, Shigeyuki ^a   Huang, Sharon ^a   Fong, Tim C ^b   Ando, Dale ^b   Burrows, Francis ^b   Jolly, Douglas J ^b   Nemunaitis, John ^c   Hoon, Dave S B ^a  

^a JOHN WAYNE CANCER INSTITUTE   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antibody; Interferon; Melanoma; Retroviral vector

Indexed keywords

GAMMA INTERFERON; GLYCOPROTEIN GP 100; IMMUNOGLOBULIN G ANTIBODY; MELANOMA ANTIGEN; MONOPHENOL MONOOXYGENASE; RECOMBINANT GAMMA INTERFERON; VIRUS VECTOR;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; HUMAN; MELANOMA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; RETROVIRUS; TREATMENT OUTCOME; TUMOR IMMUNITY;

UNIDENTIFIED RETROVIRUS;

EID: 0033778639     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700224     Document Type: Article

References (32)

1. Cancer statistics 1999
2. Prognostic clinical and pathologic features
3. Prolongation of survival in metastatic melanoma after active specific immunotherapy with a new polyvalent melanoma vaccine
4. Advantages of concurrent biochemotherapy modified by decrescendo interleukin-2, granulocyte colony-stimulating factor, and tamoxifen for patients with metastatic melanoma
5. Interferon-α2b adjuvant therapy of high-risk resected cutaneous melanoma: The Eastern Cooperative Oncology Group trial EST 1684
6. Malignant melanoma
7. Augmentation of antitumor immunity by tumor cells transduced with a retroviral vector carrying the interleukin-2 and interferon-γ cDNAs
8. Generation of a systemic antitumor response with regional intratumoral injections of interferon γ retroviral vector
9. Regional and systemic cancer therapy by direct intralesional administration of IFN-γ retroviral vector
10. Induction of antibody response to human tumor antigens by gene therapy using a fusigenic viral liposome vaccine
11. Targeting in gene therapy for gliomas
12. The nature of the principal type 1 interferon-producing cells in human blood
13. Modulation of human melanoma cells by IL-4 and in combination with γ-interferon or a-tumor necrosis factor
14. + cytotoxic T cell lines against melanoma
15. Exogenous expression of mouse interferon γ cDNA in mouse neuroblastoma C1300 cells results in reduced tumorigenicity by augmented antitumor immunity
16. Eastern cooperative group trial of interferon γ, in metastatic melanoma: An innovative study design
17. Phase I trial of interferon-γ (IFN-} retroviral vector administered intratumorally to patients with metastatic melanoma
18. Phase I trial of interferon-γ retroviral vector administered intratumorally with multiple courses in patients with metastatic melanoma
19. Melanoma patients immunized with melanoma cell vaccine induce antibody response to recombinant MAGE-A1 antigen
20. Antibody responses to melanoma/melanocyte autoantigens in melanoma patients
21. Anti-tyrosinase-related protein-2 immune response in vitiligo patients and mela noma patients receiving active-specific immunotherapy
22. Melanoma-associated antigen as messenger RNA detection markers for melanoma
23. Tyrosinase and related proteins in mammalian pigmentation
24. Molecular characterization of a human tyrosinase-related-protein-2 cDNA: Patterns of expression in melanocytic cells
25. Pigmentation genes: The tyrosinase gene family and the pmel 17 gene
26. Establishment of parameters for optimal transduction efficiency and antitumor effects with purified high-titer HSV-TK retroviral vector in established solid tumors
27. Proteasomes are regulated by interferon γ: Implications for antigen processing
28. Antigen presentation by MHC class I and its regulation by interferon γ
29. IFN-γ induction of p21(WAF1) is required for cell cycle inhibition and suppression of apoptosis
30. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21(WAF1/CIP1) mediated by STAT1
31. Autoantibodies to tyrosinase, the bridge between melanoma and vitiligo
32. The role of tyrosinase in autoimmune vitiligo